Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
33.3 USD | -0.97% | -3.57% | +65.43% |
Financials (USD)
Sales 2024 * | 145M | Sales 2025 * | 261M | Capitalization | 1.27B |
---|---|---|---|---|---|
Net income 2024 * | -140M | Net income 2025 * | -51M | EV / Sales 2024 * | 7.76 x |
Net cash position 2024 * | 142M | Net cash position 2025 * | 115M | EV / Sales 2025 * | 4.43 x |
P/E ratio 2024 * |
-8.84
x | P/E ratio 2025 * |
-23.8
x | Employees | 244 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.91% |
Latest transcript on Tarsus Pharmaceuticals, Inc.
1 day | -0.71% | ||
1 week | -3.57% | ||
Current month | +1.64% | ||
1 month | -9.53% | ||
3 months | -8.07% | ||
6 months | +105.77% | ||
Current year | +65.43% |
Managers | Title | Age | Since |
---|---|---|---|
Bobak Azamian
CEO | Chief Executive Officer | 46 | 16-12-31 |
Jeffrey Farrow
DFI | Director of Finance/CFO | 62 | 23-04-23 |
Sesha Neervannan
COO | Chief Operating Officer | 56 | 20-07-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Link
BRD | Director/Board Member | 78 | 16-12-31 |
Wendy Yarno
BRD | Director/Board Member | 68 | 20-11-18 |
Director/Board Member | 69 | 19-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +10.33% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 33.51 | -0.33% | 113 834 |
24-06-05 | 33.62 | +1.85% | 501,815 |
24-06-04 | 33.01 | +1.16% | 320,975 |
24-06-03 | 32.63 | -1.00% | 458,154 |
24-05-31 | 32.96 | -5.12% | 1,041,733 |
Delayed Quote Nasdaq, June 06, 2024 at 10:50 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.43% | 1.27B | |
+44.11% | 749B | |
+39.11% | 605B | |
-6.60% | 351B | |
+19.64% | 328B | |
+7.90% | 292B | |
+11.77% | 216B | |
-2.45% | 214B | |
+1.77% | 167B | |
+6.83% | 165B |
- Stock Market
- Equities
- TARS Stock